Wed, May 13, 10:54 AM
- Soligenix (OTCQB:SNGX +3.4%) initiates a development agreement with Emergent BioSolutions (EBS +0.4%) to implement a commercially viable, scalable production technology for RiVax, an investigational vaccine candidate to protect against ricin exposure. It will transfer the manufacturing processes and analytics to EBS to conduct further development that could lead to a commercial manufacturing collaboration.
- The company is developing RiVAx, in conjunction with its heat stabilization technology, ThermoVax, as a heat-stable biodefense vaccine. In preclinical testing, RiVax demonstrated 100% protection from lethal ricin exposure and stability up to one year at 40 degrees Celsius (132 degrees Fahrenheit). This supports the intent to stockpile the product at ambient temperature.
- The National Institute of Allergy and Infectious Diseases (NIAID) is funding the RiVax project.
- Ricin is a highly toxic protein produced in the seeds of the castor oil plant. A grain-of-salt-size dose can kill a human. It is considered a bioterror threat due to its worldwide availability as a by-product of castor oil production.
Dec. 19, 2014, 1:24 PM
- Soligenix (OTCQB:SNGX -19.3%) prices its public offering of 1,886,530 units at $1.21 per unit. Each unit consists of one share of common stock and 0.6 of a warrant to purchase one share of common stock at $1.48 per share. Closing date is December 24.
- Net proceeds will fund R&D activities and general corporate purposes.
Oct. 7, 2014, 9:54 AM
- Menlo Park, CA-based Virobay (VBAY) is set for its IPO of 3.8M shares at $12 - 14.
- The clinical stage biopharmaceutical firm develops drugs based on its cysteine cathepsin platform. Cysteine cathepsins are important enzymes in the biology of many diseases. The company believes that inhibiting these enzymes produces safer, more effective therapies. It currently focuses its efforts on inhibitors of cathepsins S and B.
- Its lead product candidates are cathepsin S inhibitors: VBY-036 for neuropathic pain and Crohn's disease and VBY-891 for psoriasis. Phase 2 development for all three indications should commence in 1H 2015 which means that meaningful product revenues are far in the distance.
- In 2013, the company generated $9.9M in collaboration revenue. Its operating loss was ($2.3M). In 1H 2015, collaboration revenue dropped to $1.1M and the loss from operations increased to ($3.6M).
- Crohn's disease-related tickers: (ABBV -1.6%)(MRK -1.2%)(RDHL +0.4%)(VBLX)(OTCPK:TKPHF)(OTCPK:TKPYY)(CNDO +1.1%)(OTCQB:SNGX)(PSTI +2.3%)
- Neuropathic pain-related tickers: (DARA -4.4%)(AVNR -3.4%)(ZLCS +0.9%)(IPCI -2%)(BLRX -1.9%)(MNOV +0.6%)(PFE -0.3%)(OTCPK:NGSX)
- Psoriasis-related tickers: (DERM -0.5%)(NVS -2.5%)(CELG -1.4%)(LLY -1.3%)(CANF -2.3%)(IDRA -1.4%)(JNJ -0.8%)(XNPT +0.5%)(HSP -0.2%)
Sep. 5, 2014, 7:24 AM
- Soligenix (OTCQB:SNGX) acquires the rights to synthetic hpericin from the Yeda Research and Development Company, Ltd., the commercial arm of the Weizmann Institute of Science in Rehovot, Israel. The product candidate, SGX301, is has been tagged an orphan drug by the FDA and is ready to enter into Phase 3 clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL).
- Synthetic hypericin is a photosensitizer that is topically applied to skin lesions and activated by fluorescent light 16 to 24 hours later. In a Phase 2 clinical trial, 58.3% of CTCL patients responded to local hypericin treatment compared to 8.3% in the placebo group. The Phase 3 protocol is currently under FDA review.
Sep. 19, 2013, 12:05 PM
- Soligenix (SNGX.OB +11.2%) jumps after announcing it has received a contract from the Biomedical Advanced Research and Development Authority for the "preclinical and manufacturing development" of the GI ARS treatment OrbeShield.
- The initial deal is for two years and can be extended for up to five total years.
- The contract is valued at up to $26.3M and will help the company "successfully navigate and complete the FDA approval process." (PR)
Sep. 16, 2013, 7:51 AM
- Soligenix (SNGX.OB) scores an orphan designation for the innate defense regulator SGX94 in patients with acute radiation syndrome.
- In clinical models, the drug minimized damage to the skin and gastrointestinal tract, and "enabled clearance of infection as a result of damage to the hematopoietic system." (PR)
Jun. 28, 2013, 7:42 AM
SNGX vs. ETF Alternatives
We are a late-stage biopharmaceutical company developing product candidates intended to address unmet medical needs in areas of inflammation, oncology, and biodefense. We maintain two active business segments: BioTherapeutics and Vaccines/BioDefense. Our BioTherapeutics business segment is... More
Other News & PR